A recent study led by John H. Curtis, part of Dr. Brian McFarlin’s research group (FACSM) at the University of North Texas, was published in the Official Journal of the American College of Sports Medicine on May 29th. This study, “Does Supplementation with Pediococcus Acidilactici Probiotics Alter Inflammatory Response to Exercise on Consecutive Days?”, examines potential sports nutrition applications of probiotics. Pediococcus acidilactici NRRL B-50517 (PA5051®), the probiotic used in the study and patented by Imagilin® Technology, is a novel plant-based, non-spore forming probiotic that can withstand high temperatures (up to 185° F) and acidic environments. Being able to endure high temperatures and acidic regions allows PA5051® to reach the gastrointestinal tract and take effect. Subjects that took PA5051® showed effects on their post-exercise inflammation, particularly in the inflammation from exercise done in consecutive days. This evaluation was done by taking blood samples from the subjects and analyzing them using both bead-based assays and a multiplex analyzer (Luminex LX200). Results published in the Official Journal of the College of Sports Medicine, Medicine & Science in Sports & Exercise, 51(5) Supplement: S357. Study sponsored by Imagilin® Technology.
When the body undergoes a strenuous workout, levels of pro-inflammatory markers (cytokines and myokines) begin to rise in the body which can lead to muscle soreness and reduced muscle strength. In the study led by John Curtis, patients were administered PA5051® for 14 days before doing intense 45-minute interval exercises for two consecutive days. Two days after the final exercise day, results showed that patients taking PA5051® had reduced pro-inflammatory markers compared to the placebo group. Not only can PA5051® efficiently sustain itself in high temperatures and acid environments, but it also functions as a way to supplement work out recovery. This study showcases the interest Imagilin® Technology has to expand into the sports and exercise field.